Centene Reports 2025 GAAP Loss Driven by Impairments, Forecasts Strong Adjusted EPS Rebound for 2026
Summary
Centene Corporation announced a GAAP loss for the full year 2025 due to significant goodwill and asset impairments, but provided optimistic 2026 guidance projecting adjusted diluted EPS to be greater than $3.00, a substantial increase from $2.08 in 2025.
Key Events
-
2025 Full Year Financial Results
Reported a GAAP diluted loss per share of $(13.53) and adjusted diluted earnings per share of $2.08 for the full year ended December 31, 2025.
-
Significant Impairment Charges
The 2025 GAAP loss was primarily driven by a $6.7 billion non-cash goodwill impairment in Q3 2025 and a $513 million impairment related to the divestiture of Magellan Health businesses in Q4 2025.
-
Strong 2026 Adjusted EPS Guidance
Provided full year 2026 guidance for adjusted diluted earnings per share of greater than $3.00, a significant increase from the $2.08 reported in 2025.
-
Operational Improvement Outlook
Management expects meaningful margin improvement and renewed adjusted diluted EPS growth in 2026, with anticipated improvements in Health Benefits Ratio (HBR) and Adjusted SG&A expense ratio.
Analysis
Centene Corporation announced a challenging financial performance for the full year 2025, reporting a significant GAAP diluted loss per share of $(13.53). This loss was primarily attributable to substantial non-cash impairment charges, including a $6.7 billion goodwill impairment in the third quarter and a $513 million impairment related to the divestiture of Magellan Health businesses in the fourth quarter. Despite these backward-looking challenges, the company provided a strong and optimistic outlook for 2026, projecting adjusted diluted earnings per share to be greater than $3.00. This guidance represents a substantial increase from the $2.08 adjusted diluted EPS reported in 2025, signaling management's confidence in achieving meaningful margin improvement and renewed earnings growth. Investors will likely focus on this forward-looking guidance as a key indicator of the company's operational turnaround and future profitability.
At the time of this filing, CNC was trading at $38.21 on NYSE in the Finance sector, with a market capitalization of approximately $19.6B. The 52-week trading range was $25.08 to $66.03. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.